Mucopolysaccharidosis type III, also known as Sanfilippo syndrome, is a rare inherited disease that primarily damages the brain and spinal cord, leading to severe intellectual decline, behavioral challenges, and progressive loss of abilities in affected children.
Understanding Mucopolysaccharidosis Type III
Mucopolysaccharidosis type III is a disorder where the body cannot properly break down certain large sugar molecules called glycosaminoglycans, which are long chains of sugars that help build tissues throughout the body. When these molecules are not broken down correctly, they accumulate inside cells, particularly in structures called lysosomes, which are like recycling centers within cells. This buildup causes progressive damage to many body systems, especially the nervous system.[1]
The condition belongs to a group of diseases called mucopolysaccharidoses. The name comes from the fact that these sugar molecules were originally called mucopolysaccharides because of their thick, jelly-like consistency. The disease is also commonly referred to as Sanfilippo syndrome, named after Dr. Sylvester Sanfilippo, one of the doctors who first described it in 1963.[6]
Children with MPS III typically appear normal at birth and may develop normally during their first year of life. However, as the harmful substances continue to build up in their cells, symptoms gradually begin to appear, usually between the ages of one and four years. The disease causes progressive damage that worsens over time, affecting learning, behavior, movement, and many body functions.[3]
Epidemiology: How Common Is This Disease
Mucopolysaccharidosis type III is the most common form among all types of mucopolysaccharidosis disorders. Researchers estimate that it affects approximately 1 in 70,000 newborns overall, though this number can vary depending on the population studied. Some research suggests the prevalence may range anywhere from 1 in 50,000 to 1 in 250,000 births in different regions.[1]
The disease occurs in families of all ethnic backgrounds, but certain subtypes are more common in specific geographic areas. Type A is more prevalent in Northern and Eastern Europe, while Type B occurs more frequently in Southern European countries, particularly Mediterranean regions. Types C and D are much rarer worldwide, with estimated incidences of approximately 1 in 1,500,000 and 1 in 1,000,000 respectively.[13]
In Saudi Arabia, the incidence rate has been estimated at about 2 per 100,000 live births. The condition appears to occur more frequently in populations where marriages between blood relatives are common, as this increases the chance that both parents carry the same genetic mutation.[7]
The actual number of people living with MPS III is likely higher than reported, as many cases may be delayed in diagnosis or missed entirely, especially in patients with slower-progressing forms of the disease. This underdiagnosis means that families may struggle for years before receiving answers about their child’s condition.[13]
Causes: What Triggers This Disease
Mucopolysaccharidosis type III is caused by genetic defects in specific genes that provide instructions for making enzymes needed to break down heparan sulfate, a particular type of glycosaminoglycan. When these enzymes are missing or don’t work properly, heparan sulfate cannot be properly broken down and begins to accumulate inside cells throughout the body.[1]
There are four main subtypes of MPS III, each caused by a defect in a different gene. Type A results from mutations in the SGSH gene, which leads to a deficiency of an enzyme called heparan N-sulfatase. Type B is caused by defects in the NAGLU gene, resulting in insufficient alpha-N-acetylglucosaminidase enzyme. Type C stems from mutations in the HGSNAT gene, affecting the acetyl-CoA:alpha-glucosaminide N-acetyltransferase enzyme. Finally, Type D is caused by defects in the GNS gene, leading to a shortage of N-acetylglucosamine 6-sulfatase enzyme.[4]
The disease is inherited in an autosomal recessive pattern, which means a child must receive one defective gene copy from each parent to develop the condition. Parents who carry one copy of the mutated gene typically do not show symptoms themselves but are called carriers. When both parents are carriers, each of their children has a 25 percent chance of inheriting both defective genes and developing the disease, a 50 percent chance of being a carrier like the parents, and a 25 percent chance of inheriting two normal genes.[4]
The accumulation of heparan sulfate disrupts normal cell function in multiple ways. It causes cells to malfunction, triggers abnormal gene expression affecting hundreds of genes, and leads to damage in various cell structures and biochemical processes. The brain and spinal cord are particularly vulnerable to this damage, which explains why neurological symptoms are the most severe features of the disease.[1]
Risk Factors: Who Is More Likely to Develop This Disease
The primary risk factor for developing mucopolysaccharidosis type III is having parents who both carry a mutation in one of the four genes associated with the disease. Family history plays a crucial role, as the condition runs in families where the genetic mutation has been passed down through generations.[4]
Consanguinity, or marriages between blood relatives such as cousins, significantly increases the risk. In communities where such unions are culturally common, the likelihood that both parents carry the same recessive genetic mutation is higher. This explains why certain populations with high rates of consanguineous marriages see increased prevalence of MPS III.[7]
Geographic and ethnic background can influence risk, as different subtypes occur more frequently in specific populations. Families of Northern European, Eastern European, or Mediterranean descent may have slightly different risk profiles depending on which subtype is more common in their ancestral region. However, it’s important to note that MPS III can affect any family regardless of ethnic or racial background.[13]
Families who already have one child with MPS III face a 25 percent risk with each subsequent pregnancy. Siblings of affected children have a two in three chance of being carriers of the genetic mutation, even if they don’t show symptoms. Understanding these risks is important for family planning and helps families make informed decisions about future pregnancies.[6]
Symptoms: How This Disease Affects Patients
Children with mucopolysaccharidosis type III generally do not display symptoms at birth and initially appear to develop normally. The first signs typically become noticeable during early childhood, most commonly between ages one and four years. These early symptoms can be subtle and easily overlooked, which often leads to delays in diagnosis.[3]
One of the most common early signs is delayed speech and language development. Children may be slower than their peers to start talking or may struggle to learn new words and form sentences. Some children show mild delays in reaching developmental milestones such as walking or learning self-care skills. However, these delays might not immediately raise concerns, as they can be relatively mild in the beginning.[5]
Behavioral problems often become the most noticeable and challenging symptoms as the disease progresses. Children typically become increasingly hyperactive, restless, and difficult to manage. They may display aggressive or destructive behavior, have frequent temper tantrums, and show little fear of danger, which can lead to safety concerns. Many affected children develop an increased tendency to put objects in their mouths, chew on things excessively, or swallow inappropriate items, a behavior called hyperorality.[1]
Sleep disturbances represent another major symptom that significantly impacts both the child and their family. Children with MPS III often have great difficulty falling asleep, wake frequently during the night, or may reverse their sleep-wake cycles entirely. These sleep problems can persist for years and create tremendous stress for caregivers who must manage around-the-clock care.[3]
Some children display features similar to autism spectrum disorder, including difficulty with social interactions, communication challenges, and repetitive behaviors. This overlap can sometimes lead to an initial misdiagnosis, delaying the correct identification of MPS III.[1]
As the disease advances, children experience progressive intellectual decline and loss of previously learned skills, a process called developmental regression. They gradually lose the ability to speak, understand language, and perform tasks they once could do. In later stages, most children develop seizures, lose the ability to walk, and require wheelchairs. Movement disorders and swallowing difficulties become common, and many children eventually become unresponsive.[3]
Physical symptoms, while generally milder than the neurological ones, can also occur. These may include a slightly enlarged liver or spleen, mildly coarse facial features with a prominent forehead, thick hair and eyebrows, and a large head size. Some children have recurring ear and respiratory infections, chronic diarrhea, or hernias in the belly button or groin area. Joint stiffness and bone abnormalities may develop, though these are usually less severe than in other types of mucopolysaccharidosis.[1]
Heart problems can develop, including weakening of the heart muscle, irregular heart rhythms, or issues with heart valves. Hearing loss and vision problems may also occur as the disease progresses. The severity and speed of symptom progression varies considerably, even among children with the same subtype of MPS III.[1]
Prevention: Can This Disease Be Prevented
Currently, there is no way to prevent mucopolysaccharidosis type III once a child inherits the genetic mutations from both parents. However, families can take steps to identify their risk and make informed reproductive decisions through genetic counseling and testing services.[4]
Genetic counseling is recommended for couples who have a family history of MPS III or who have already had an affected child. Professional genetic counselors can help families understand their risks, explain inheritance patterns, and discuss available options for future pregnancies. This service provides emotional support and practical information during what can be a very difficult time.[2]
Carrier testing can identify whether individuals carry a mutation in one of the genes associated with MPS III, even before they have children or show any symptoms. This testing is particularly valuable for siblings of affected children, as they have a two in three chance of being carriers. Prospective parents from populations with higher rates of MPS III or those with known family history may choose carrier screening before conception.[6]
Prenatal testing is available for families at risk. Two main procedures can be performed during pregnancy: amniocentesis, which analyzes fluid surrounding the baby, and chorionic villus sampling, which examines tissue from the placenta. These tests can definitively determine whether a developing baby has inherited the genetic mutations that cause MPS III. Some families use this information to prepare for a child with special needs, while others may make different reproductive choices based on the results.[4]
For families with a high risk of having another affected child, reproductive options such as in vitro fertilization with genetic testing of embryos before implantation may be available. These advanced techniques allow selection of embryos without the disease-causing mutations. However, access to such technologies varies by location and involves significant cost and ethical considerations.[2]
While these measures cannot prevent MPS III in the population at large, they empower individual families to understand their risks and make choices aligned with their values and circumstances. Public health measures to increase awareness among healthcare providers and at-risk communities can also help ensure earlier diagnosis and connection to appropriate support services.[13]
Pathophysiology: How the Disease Changes the Body
The fundamental problem in mucopolysaccharidosis type III involves the incomplete breakdown of heparan sulfate, a complex sugar molecule that is normally present throughout the body. In healthy individuals, special enzymes inside lysosomes systematically break down heparan sulfate when it has served its purpose, allowing the components to be recycled or eliminated.[1]
In MPS III, one of four critical enzymes needed for this breakdown process is either missing or doesn’t function properly. Without this enzyme, the step-by-step degradation of heparan sulfate stops at a specific point. As a result, partially broken-down heparan sulfate molecules begin to accumulate within the lysosomes of cells throughout the body.[6]
As these storage compartments become increasingly packed with undegraded material, they swell and disrupt normal cell function. The accumulation triggers a cascade of secondary problems within cells. Gene expression patterns change dramatically, with hundreds of genes showing abnormal activity levels. Critical cellular processes become impaired, including energy production, protein synthesis, and communication between cells.[1]
The brain and spinal cord are particularly vulnerable to this storage process. Neurons, the nerve cells that transmit signals throughout the nervous system, are especially sensitive to disruption. As storage material accumulates over years, neurons begin to malfunction and eventually die. This progressive loss of brain cells, called neurodegeneration, directly causes the intellectual decline, behavioral changes, and loss of motor skills seen in affected children.[7]
The disease also affects other organ systems, though usually less severely than the nervous system. In the liver and spleen, storage causes mild enlargement as cells become bloated with accumulated material. In bones and joints, the buildup interferes with normal growth and development, leading to skeletal abnormalities and stiffness. Heart tissue can be affected, with storage in heart valves causing them to thicken and potentially malfunction.[1]
Inflammation appears to play a significant role in the disease process. The abnormal accumulation of heparan sulfate triggers inflammatory responses within tissues, which contributes to ongoing damage. This chronic inflammation, combined with direct toxic effects of the stored material, creates a self-perpetuating cycle of cellular injury.[7]
Different subtypes of MPS III result from deficiencies in different enzymes, but all lead to the same endpoint: accumulation of heparan sulfate. Type A typically causes the most rapid and severe progression, while some individuals with Type B may have slower disease courses. However, even within the same subtype and even within the same family, the rate and severity of disease progression can vary considerably, suggesting that other genetic or environmental factors may influence how the disease unfolds.[1]
Diagnosis and Testing
Diagnosing mucopolysaccharidosis type III typically begins when parents or healthcare providers notice developmental delays, behavioral problems, or other concerning symptoms. Because the early signs can be subtle and nonspecific, diagnosis is often delayed. The process usually involves several steps, starting with clinical evaluation and progressing to specific laboratory tests.[2]
A healthcare provider will first perform a thorough physical examination, looking for characteristic features such as coarse facial appearance, enlarged liver or spleen, joint stiffness, or other physical signs. A detailed medical and family history helps identify patterns that might suggest an inherited condition. However, physical features in MPS III are often mild, especially in young children, making clinical diagnosis challenging.[4]
Urine testing represents a valuable screening tool. Children with MPS III excrete large amounts of heparan sulfate in their urine, which can be detected through specialized tests. A urine mucopolysaccharide screen can indicate whether elevated levels of these substances are present. If the screening test is positive or if clinical suspicion remains high, more specific testing follows.[4]
Definitive diagnosis requires demonstrating either deficiency of one of the four specific enzymes or identifying disease-causing mutations in the corresponding genes. Enzyme activity can be measured in blood samples or in cells cultured from a skin sample. These tests determine which of the four subtypes of MPS III a child has by identifying which enzyme is deficient.[2]
Genetic testing analyzes DNA to identify mutations in the SGSH, NAGLU, HGSNAT, or GNS genes. This testing can confirm the diagnosis, identify the specific subtype, and provide information useful for family planning and genetic counseling. Genetic testing can also be performed on family members to determine carrier status.[4]
Additional tests may be performed to assess the extent of disease involvement in different organ systems. These might include echocardiograms to evaluate heart function, X-rays to assess bone abnormalities, eye examinations to check for vision problems, and hearing tests. Brain imaging with MRI may show characteristic changes, though these are not always present in early stages.[4]
Early diagnosis is critical but challenging. Many children go through years of evaluations, including assessments for autism, behavioral disorders, or intellectual disability, before the correct diagnosis is made. Increased awareness among healthcare providers and broader implementation of newborn screening could help identify affected children sooner, potentially opening the door to earlier intervention when future treatments become available.[13]
Treatment and Management
Currently, there is no cure for mucopolysaccharidosis type III, and no treatments have been approved that can stop or reverse the underlying disease process. Management focuses entirely on supportive care aimed at maximizing quality of life, managing symptoms, and providing comfort for affected children and support for their families.[6]
Behavioral and psychiatric symptoms require careful management. Medications may help control hyperactivity, aggression, anxiety, and sleep disturbances, though behavioral therapy alone is often less effective than in other conditions. Finding the right medication combinations often involves trial and error, as each child responds differently. Sleep medications or structured sleep routines may help manage the severe sleep problems that affect most children with MPS III.[2]
Supportive therapies for developmental delays include early intervention services, special education programs, speech therapy, and occupational therapy. While these interventions cannot prevent disease progression, they can help children maintain skills longer and improve their quality of life during earlier disease stages. Physical therapy helps manage joint stiffness and maintain mobility for as long as possible.[2]
Regular monitoring by multiple specialists is essential. Neurologists track disease progression and manage seizures when they develop. Cardiologists monitor heart function and treat any cardiac complications. Orthopedic specialists address skeletal problems and may recommend devices to support mobility. Ear, nose, and throat specialists manage recurring infections. Audiologists monitor hearing, and ophthalmologists check for vision problems.[9]
As the disease progresses, feeding becomes increasingly difficult due to swallowing problems. Nutritionists can help ensure adequate nutrition, and in some cases, feeding tubes may be necessary to maintain proper nutrition and prevent aspiration, which occurs when food or liquid enters the lungs. Respiratory problems may require treatment with medications or breathing support devices.[2]
Families need extensive support to manage the challenges of caring for a child with MPS III. Respite care services can provide temporary relief for exhausted caregivers. Support groups connect families facing similar challenges, allowing them to share experiences and coping strategies. Psychological counseling helps families process the emotional burden of caring for a child with a progressive, life-limiting condition.[18]
Special precautions are necessary for any procedures requiring anesthesia, as children with MPS III may have anatomical differences in their airways that complicate airway management. Surgeries should be performed only in centers with experience caring for patients with complex airway issues. Hip surgery carries particular risks and is generally avoided when possible.[2]
Families should work with social workers and care coordinators to access available resources, which may include medical equipment, home modifications for safety, and financial assistance programs. Planning for the child’s evolving care needs requires ongoing reassessment and coordination among multiple healthcare providers and community services.[13]
Research and Future Treatments
Although no approved treatments currently exist for MPS III, extensive research is underway exploring multiple therapeutic approaches. These investigational strategies include gene therapy, enzyme replacement therapy, substrate reduction therapy, and other innovative techniques, with several in various stages of clinical trials.[11]
Gene therapy approaches aim to deliver a working copy of the defective gene into cells, allowing them to produce the missing enzyme. Several clinical trials are testing different methods of gene delivery, including one approach using a virus called AAV9 to carry the corrected gene into brain and other cells. Early results from these studies are being carefully evaluated to determine safety and effectiveness.[11]
Enzyme replacement therapy, which has been successful for some other types of mucopolysaccharidosis, faces a major challenge in MPS III: the blood-brain barrier. This protective barrier prevents large molecules like replacement enzymes from entering the brain from the bloodstream. Researchers are investigating methods to deliver enzymes directly into the brain and spinal fluid, bypassing this barrier.[9]
Substrate reduction therapy attempts to reduce the production of heparan sulfate, thereby decreasing the amount that accumulates in cells. Compounds like genistein, a naturally occurring plant chemical, have shown promise in laboratory and animal studies by reducing the synthesis of glycosaminoglycans. Clinical trials are evaluating whether this approach can slow disease progression.[9]
Bone marrow or stem cell transplantation has been attempted in MPS III patients but has shown disappointing results compared to its success in other mucopolysaccharidosis types. The procedure carries significant risks, and limited benefit has been demonstrated for the neurological symptoms that are most problematic in MPS III.[6]
Lessons from animal studies and early clinical trials have emphasized that timing is crucial. Treatments appear most likely to be effective when started early, before extensive neuronal death has occurred. This understanding has increased urgency around developing newborn screening programs that could identify affected babies before symptoms begin.[11]
Families interested in participating in research studies or clinical trials should discuss options with their medical team. Patient advocacy organizations, such as the National MPS Society, maintain updated information about ongoing research studies and can help connect families with research opportunities. Participation in research helps advance understanding of the disease and may provide access to experimental treatments.[6]
Prognosis and Life Expectancy
Mucopolysaccharidosis type III causes progressive neurological decline in all affected individuals, though the rate of progression varies considerably. Most children with MPS III live into their teenage years, with some surviving into early or mid-adulthood. A smaller number with rapidly progressing disease may die at younger ages, while others with more slowly progressive forms may live into their twenties, thirties, or beyond.[1]
Type A typically represents the most severe form, with earlier symptom onset and faster progression than the other subtypes. Children with Type A often show symptoms earlier in childhood and experience more rapid deterioration. However, even within Type A, substantial variation exists between individuals, and the same is true for the other subtypes.[4]
The disease course can be thought of as occurring in phases, though these overlap and blur together. Early in the disease, children may show relatively mild developmental delays and behavioral problems. During middle phases, behavioral disturbances often become most severe and difficult to manage, with hyperactivity, aggression, and sleep problems at their worst. In later stages, behavioral problems often diminish, but this reflects disease progression as children lose cognitive function and become less mobile and responsive.[3]
Death usually results from complications of neurological decline, respiratory infections, or aspiration pneumonia. As children lose the ability to swallow properly and become immobile, they become increasingly vulnerable to breathing problems and infections that eventually prove fatal.[2]
Some individuals with extremely attenuated, slowly progressive forms of MPS III may not show symptoms until later childhood or even adulthood. These rare cases may present primarily with early-onset dementia, with or without a history of intellectual disability. The existence of such variability makes predicting individual outcomes difficult and emphasizes the importance of viewing MPS III as a spectrum rather than a single uniform disease.[2]
The burden on families cannot be overstated. Caring for a child with progressive neurological decline creates enormous emotional, physical, and financial strain. As children lose skills and abilities they once had, families must continuously adapt their care approaches. The severe behavioral problems and sleep disturbances that characterize middle disease phases are particularly exhausting for caregivers. Many families benefit from palliative care services focused on comfort and quality of life as the disease advances.[18]
